Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Return on Equity (2019 - 2021)

Historic Return on Equity for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q3 2021 value amounting to 0.38%.

  • Black Diamond Therapeutics' Return on Equity fell 2200.0% to 0.38% in Q3 2021 from the same period last year, while for Sep 2021 it was 0.38%, marking a year-over-year decrease of 2200.0%. This contributed to the annual value of 0.5% for FY2020, which is 14200.0% down from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Return on Equity of 0.38% as of Q3 2021, which was down 2200.0% from 0.27% recorded in Q2 2021.
  • Black Diamond Therapeutics' 5-year Return on Equity high stood at 0.66% for Q4 2019, and its period low was 0.38% during Q3 2021.
  • Moreover, its 3-year median value for Return on Equity was 0.18% (2021), whereas its average is 0.03%.
  • In the last 5 years, Black Diamond Therapeutics' Return on Equity crashed by -8700bps in 2020 and then skyrocketed by 600bps in 2021.
  • Over the past 3 years, Black Diamond Therapeutics' Return on Equity (Quarter) stood at 0.66% in 2019, then crashed by -131bps to 0.21% in 2020, then crashed by -84bps to 0.38% in 2021.
  • Its Return on Equity was 0.38% in Q3 2021, compared to 0.27% in Q2 2021 and 0.18% in Q1 2021.